Stevanato Group/$STVN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Stevanato Group
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.
Ticker
$STVN
Sector
Primary listing
NYSE
Employees
5,521
Headquarters
Piombino Dese, Italy
Website
Stevanato Group Metrics
BasicAdvanced
$6.6B
40.99
$0.59
0.56
$0.06
0.26%
Price and volume
Market cap
$6.6B
Beta
0.56
52-week high
$28.00
52-week low
$17.49
Average daily volume
279K
Dividend rate
$0.06
Financial strength
Current ratio
1.892
Quick ratio
1.303
Long term debt to equity
25.611
Total debt to equity
31.409
Dividend payout ratio (TTM)
20.75%
Interest coverage (TTM)
19.34%
Profitability
EBITDA (TTM)
315.269
Gross margin (TTM)
28.72%
Net profit margin (TTM)
12.02%
Operating margin (TTM)
17.54%
Effective tax rate (TTM)
25.22%
Revenue per employee (TTM)
$243,070
Management effectiveness
Return on assets (TTM)
5.55%
Return on equity (TTM)
10.19%
Valuation
Price to earnings (TTM)
40.987
Price to revenue (TTM)
4.87
Price to book
4.59
Price to tangible book (TTM)
4.84
Price to free cash flow (TTM)
-158.213
Free cash flow yield (TTM)
-0.63%
Free cash flow per share (TTM)
-0.153
Dividend yield (TTM)
0.26%
Forward dividend yield
0.26%
Growth
Revenue change (TTM)
6.98%
Earnings per share change (TTM)
19.61%
3-year revenue growth (CAGR)
8.19%
3-year earnings per share growth (CAGR)
-1.04%
3-year dividend per share growth (CAGR)
1.92%
What the Analysts think about Stevanato Group
Analyst ratings (Buy, Hold, Sell) for Stevanato Group stock.
Bulls say / Bears say
Stevanato reported revenue of €280.0 million for Q2 2025, up 8% year-over-year, driven by strong performance in its Biopharmaceutical and Diagnostic Solutions segment, while maintaining full-year 2025 guidance of €1.16-1.19 billion.
The company secured €200 million in financing to support capacity expansions at its Cisterna di Latina and Fishers, Indiana facilities, reinforcing its ability to meet growing demand in the GLP-1 and broader biologics markets.
In fiscal year 2024, Stevanato achieved record revenue of €1,104 million, with high-value solutions accounting for 45% of segment revenue, underscoring its leading market position in high-performance syringe offerings.
Gross profit margin in fiscal year 2024 decreased to 28.7% due to temporary vial destocking and start-up inefficiencies at new manufacturing sites, signaling potential volatility in profitability.
The Engineering segment revenue declined by 17% in fiscal 2024, reflecting ongoing challenges in project execution and weighing on overall segment profitability.
Tariff programs are estimated to impact operating profit by approximately €4.5 million in fiscal 2025, highlighting susceptibility to geopolitical trade tensions between Europe and the U.S.
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2025.
Stevanato Group Financial Performance
Revenues and expenses
Stevanato Group Earnings Performance
Company profitability
Stevanato Group News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Stevanato Group stock?
Stevanato Group (STVN) has a market cap of $6.6B as of November 12, 2025.
What is the P/E ratio for Stevanato Group stock?
The price to earnings (P/E) ratio for Stevanato Group (STVN) stock is 40.99 as of November 12, 2025.
Does Stevanato Group stock pay dividends?
Yes, the Stevanato Group (STVN) stock pays dividends to shareholders. As of November 12, 2025, the dividend rate is $0.06263 and the yield is 0.26%. Stevanato Group has a payout ratio of 20.75% on a trailing twelve-month basis.
When is the next Stevanato Group dividend payment date?
The next Stevanato Group (STVN) dividend payment date is unconfirmed.
What is the beta indicator for Stevanato Group?
Stevanato Group (STVN) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.